Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Pharmacotherapy

• Publication date

  2010-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1592/phco.30.8.787PMID 20653354
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy.

  2010cited by this paper
• Response to Letter by van Werkum: Proton pump inhibitors and clopidogrel: a difficult dilemma

  2009cited by this paper
• Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

  2009cited by this paper
• Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome

  2009cited by this paper
• A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

  2009cited by this paper
• Genetic determinants of response to clopidogrel and cardiovascular events.

  2009cited by this paper
• Cytochrome p-450 polymorphisms and response to clopidogrel.

  2009cited by this paper
• Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

  2009cited by this paper
• Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

  2009cited by this paper
• Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

  2009cited by this paper
• Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.

  2009cited by this paper
• Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

  2008cited by this paper
• Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

  2008cited by this paper
• Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors.

  2008cited by this paper
• The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance

  2008cited by this paper
• Abstract 3999: Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial

  2008cited by this paper
• ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

  2008cited by this paper
• ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

  2008cited by this paper
• Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

  2004cited by this paper
• Pharmacogenomics of proton pump inhibitors.

  2004cited by this paper
• Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism

  2002cited by this paper
• The assessment of refill compliance using pharmacy records: methods, validity, and applications.

  1997cited by this paper

• Increased Risk of Ischemic Events in Patients With Stroke Treated With Clopidogrel and a P-CAB or PPI.

  2026cites this paper
• Drug utilization pattern and adverse drug reaction monitoring in the cardiac emergency of a tertiary care teaching hospital: An observational study

  2025cites this paper
• Risk of stroke associated with proton pump inhibitor use among individuals with and without pre-existing cardiovascular diseases: a systematic review and meta-analysis

  2025cites this paper
• Concomitant use of clopidogrel and proton pump inhibitors: A retrospective analysis of prescription behaviour

  2025cites this paper
• A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients

  2024cites this paper
• Role of Proton Pump Inhibitors in Cardiac Patients: Guideline Recommendations Versus Practical Approach

  2024cites this paper
• Proton pump inhibitors and cardiovascular risk: a critical review

  2024cites this paper
• CYP2C19 loss‐of‐function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel

  2023cites this paper
• Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients with Type 2 Diabetes.

  2022cites this paper
• Clinical Outcomes of Concomitant Use of Proton Pump Inhibitors and Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis

  2021cites this paper
• The Association between Co-Administration of Omeprazole and Clopidogrel and Cardiovascular Outcomes

  2021cites this paper
• Ethnic variance on long term clinical outcomes of concomitant use of proton pump inhibitors and clopidogrel in patients with stent implantation

  2021influential citation
• PPIs and Safety Concerns - A Pending Verdict?

  2021cites this paper
• Clopidogrel efficacy with concomitant drug therapy in patients undergoing percutaneous coronary intervention

  2020cites this paper
• Clopidogrel drug interactions: a review of the evidence and clinical implications

  2020cites this paper
• Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention

  2019cites this paper
• Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents

  2019cites this paper
• Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.

  2019cites this paper
• Outcome of stroke patients on clopidogrel plus proton-pump inhibitors: a single-center cohort study

  2019cites this paper
• Effectiveness and Safety of Clopidogrel Co‐administered With Statins and Proton Pump Inhibitors: A Korean National Health Insurance Database Study

  2019cites this paper
• Meta-analysis of efficacy and safety of proton pump inhibitors with dual antiplatelet therapy for coronary artery disease.

  2019cites this paper
• Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel.

  2019cites this paper
• [The relationship between the combined use of various proton pump inhibitors with antiplatelet drugs and the risk of cardiovascular complications].

  2019cites this paper
• Are there different evidence thresholds for genomic vs. clinical precision medicine? A VOI-based framework applied to antiplatelet drug therapy

  2019cites this paper
• Systematic review with meta‐analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel

  2018influential citation
• Proton pump inhibitors and the risk of severe adverse events - A cardiovascular bombshell?

  2018cites this paper
• PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel—A Systematic Review and Meta-Analysis

  2018cites this paper
• Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis

  2018cites this paper
• Response by Malhotra et al to the Letters Regarding Article, "Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis".

  2018cites this paper
• Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype

  2018cites this paper
• Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2

  2018cites this paper
• Safety assessment of omeprazole use: a review

  2018cites this paper
• Antiplatelet therapy guided by thrombelastography in patients with acute coronary syndromes ( TEGCOR Study )

  2018cites this paper
• Proton pump inhibitors and the risk of severe adverse events – A cardiovascular bombshell?

  2018cites this paper
• Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease

  2017cites this paper
• Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study

  2017cites this paper
• Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers

  2017cites this paper
• Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes.

  2017cites this paper
• Évaluation de deux interactions médicamenteuses faisant intervenir une enzyme distincte et de leurs conséquences sur la morbi-mortalité

  2017cites this paper
• Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial

  2017cites this paper
• Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs.

  2017cites this paper
• Genotyping of CYP2C19 helps to reassure sufficient effects of antiplatelet therapy in combination with proton pump inhibitors (PPIs)

  2016cites this paper
• Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis

  2016cites this paper
• Changes in CYP2C19 enzyme activity evaluated by the [13C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity

  2016cites this paper
• Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.

  2016cites this paper
• Is personalized medicine a dream or a reality?

  2015cites this paper
• Initiation of Pharmaceutical Care Service in Medical Intensive Care Unit with Drug Interaction Monitoring Program

  2015cites this paper
• Addressing phenoconversion: the Achilles' heel of personalized medicine

  2015cites this paper
• Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy: Systematic Review

  2015cites this paper
• Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study

  2015cites this paper
• The influence of proton pump inhibitors on the effect of clopidogrel on the risk of recurrent ischemic stroke

  2015cites this paper
• Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors

  2015cites this paper
• Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

  2015cites this paper
• Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis

  2015cites this paper
• Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers.

  2015cites this paper
• Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review

  2015cites this paper
• Influence of the Concomitant Use of Clopidogrel and Proton Pump Inhibitors on Adverse Cardiovascular Events in Korean Patients with Acute Coronary Syndrome

  2014cites this paper
• A limited number of prescribed drugs account for the great majority of drug-drug interactions

  2014cites this paper
• Antiplatelet drug interactions with proton pump inhibitors

  2014influential citation
• The Impact of proton pump inhitors (PPIs) on platelet function for patients on clopidogrel for acute coronary syndrome(ACS)

  2014cites this paper
• Big data: the next frontier for innovation in therapeutics and healthcare

  2014cites this paper
• Proton pump inhibitors and clopidogrel: an association to avoid?

  2014cites this paper
• Role of CYP450 in Antiplatelet Therapy: Considerations for Patients at Risk for Further Cardiovascular or Cerebrovascular Problems

  2013cites this paper
• Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials

  2013cites this paper
• Pharmacodynamic Impacts of Proton Pump Inhibitors on the Efficacy of Clopidogrel In Vivo—A Systematic Review

  2013cites this paper
• No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis.

  2013influential citation
• What's new about clopidogrel.

  2013cites this paper
• Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: Risk of coronary events and peptic ulcer bleeding

  2013cites this paper
• Safety of Proton Pump Inhibitors

  2013cites this paper
• Upper Gastrointestinal Symptoms and Cardiovascular Disease

  2013cites this paper
• Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients

  2013cites this paper
• Antiplatelet therapy and proton pump inhibition: cause for concern?

  2012cites this paper
• Pharmacogenetics and anaesthesia: the value of genetic profiling

  2012cites this paper
• The Clinical Relevance of the Clopidogrel–Proton Pump Inhibitor Interaction

  2012cites this paper
• Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial

  2012cites this paper
• The clopidogrel-PPI interaction: an updated mini-review.

  2012cites this paper
• Esomeprazole Compared With Famotidine in the Prevention of Upper Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome or Myocardial Infarction

  2012cites this paper
• Antiplatelet Therapy and Proton Pump Inhibition: Clinician Update

  2012cites this paper
• An insight into the interaction between clopidogrel and proton pump inhibitors.

  2012cites this paper
• Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review

  2012cites this paper
• Clopidogrel

  2012cites this paper
• Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis.

  2012cites this paper
• Proton Pump Inhibitors and Clopidogrel: A Review of the Interaction

  2012cites this paper
• Phenocopy and phenoconversion: do they complicate association studies?

  2012cites this paper
• Clinical decision support for personalized medicine: an opportunity for pharmacist-physician collaboration.

  2012cites this paper
• Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions

  2012cites this paper
• Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.

  2012cites this paper
• Lack of Significant Interactions Between Clopidogrel and Proton Pump Inhibitor Therapy: Meta-Analysis of Existing Literature

  2012cites this paper
• Recent safety concerns with proton pump inhibitors.

  2012influential citation
• Antiplatelet Therapy and Proton Pump Inhibition

  2012cites this paper
• Effect of the Clopidogrel–Proton Pump Inhibitor Drug Interaction on Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome

  2012cites this paper
• Drug-drug interactions in cardiovascular catheterizations and interventions.

  2012cites this paper
• Clopidogrel and proton pump inhibitors--where do we stand in 2012?

  2012cites this paper
• on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions the American College of Cardiology Foundation/American Heart Association Task Force 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A Report of

  2012cites this paper
• Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors

  2012cites this paper
• Impact of Concomitant Use of Clopidogrel and Proton Pump Inhibitor on Clinical Outcome in Coronary Stented Patients: A Retrospective Study

  2012cites this paper
• Cardiovascular Angiography and Interventions Association Task Force on Practice Guidelines and the Society for Report of the American College of Cardiology Foundation/American Heart 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A

  2012cites this paper
• New look at antiplatelet agent‐related peptic ulcer: An update of prevention and treatment

  2012cites this paper
• Clinical use of clopidogrel.

  2012cites this paper
• Proton-pump inhibitors: the devil or the savior for patients undergoing percutaneous coronary intervention?

  2012cites this paper